<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83639">
  <stage>Registered</stage>
  <submitdate>24/02/2009</submitdate>
  <approvaldate>14/07/2009</approvaldate>
  <actrnumber>ACTRN12609000575235</actrnumber>
  <trial_identification>
    <studytitle>Antiretroviral therapy intensification with raltegravir and/or hyper-immune bovine colostrum in  Human Immunodeficiency Virus-1 (HIV-1) infected patients with suboptimal immunological response</studytitle>
    <scientifictitle>Randomised double-blind placebo controlled study to measure the effect of antiretroviral therapy (ART) intensification with raltegravir and/or hyper-immune bovine colostrum on CD4+ T cell count in ART treated, Human Immunodeficiency Virus-1 (HIV-1) infected individuals with suboptimal CD4+ T cell responses despite prolonged virologic suppression</scientifictitle>
    <utrn />
    <trialacronym>CORAL</trialacronym>
    <secondaryid>ClinicalTrials.gov ID number NCT00772590</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Human Immunodeficiency Virus (HIV)Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intensification of antiretroviral therapy with oral raltegravir and or oral hyper-immune bovine colostrum 48 weeks.
Particiapants be be randomly allocated to one of four arms of the study
I. Raltegravir 400mg (1 tablet) twice daily + hyper-immune bovine colostrum placebo (3 tablets) twice daily
II. Raltegravir placebo (1 tablet) twice daily + hyper-immune bovine colostrum 1800mg (3 tablets) twice daily
III. Raltegravir 400mg (1 tablet) twice daily + hyper-immune bovine colostrum 1800mg (3 tablets) twice daily
IV. Raltegravir placebo (1 tablet) twice daily + hyper-immune bovine colostrum placebo (3 tablets) twice daily</interventions>
    <comparator>raltegravir placebo is made to match the 400mg raltegravir image and is made of lactose monhydrate, cellulose- microcrystalline, Magnesium stearate (non bovine), Purified water (removed during processing) and Opadry II  Pink (85F94224)   

Hyper-immune bovine colostrum placebo is made to match the 600mg hyper-immune bovine colostrum image. It is made of 
Milk Protein Concentrate .</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline of CD4+ T cell count of comparisons 1) raltegravir versus placebo and 2) hyper-immune bovine colostrum versus placebo as measured in peripheral blood</outcome>
      <timepoint>Primary assessment will be done at 24 weeks from baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in T cell count, T cell percentage,  activated T cells, microbial translocation markers, plasma HIV Ribonucleic Acid (RNA) - with limit of detection of 0.4 HIV RNA copies/mL, immune activation markers and  proportion of patients with CD4+ T cells greater than 350 cells/microlitre over 48 weeks</outcome>
      <timepoint>24 weeks and 48 weeks from baseline</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Documented HIV-1 infection
2.	 Age &gt;18 years
3.	Signed informed consent
4.	Receiving combination ART for at least 12 months with a stable cART regimen for a minimum of 6 months. 
5.	Two consecutive plasma HIV RNA viral load measurements &lt;50 in the 9 months preceding the screening visit. 
6.	CD4+ T cell count &lt;350 cells/µL throughout the 6 months preceding the screening visit with &lt;50 cells/µL increase in the last 12 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Receiving a cART regimen containing an integrase inhibitor
2.	Anticipated change of cART in the 24 weeks following randomisation
3.	Participating in study with an investigational compound or device within 30 days of signing informed consent
4.	Use of immune modulating therapies or immunosuppressive medications within 60 days prior to study entry. Patients using inhaled or nasal steroids are not excluded
5.	Pregnant or breastfeeding woman
6.	Cows milk allergy
7.	Concurrent treatment with phenobarbitol, phenytoin or rifampicin.
8.	A known cause of impaired CD4+ T cell gain: for example individuals whose current cART regimen contains both tenofovir and didanosine</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>16/03/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>72</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2010</postcode>
    <postcode>2134</postcode>
    <postcode>2065</postcode>
    <postcode>2480</postcode>
    <postcode>2170</postcode>
    <postcode>2031</postcode>
    <postcode>2050</postcode>
    <postcode>3053</postcode>
    <postcode>3141</postcode>
    <postcode>3004</postcode>
    <postcode>4001</postcode>
    <postcode>4101</postcode>
    <postcode>4220</postcode>
    <postcode>4560</postcode>
    <postcode>6160</postcode>
    <postcode>6000</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of New South Wales (UNSW)</primarysponsorname>
    <primarysponsoraddress>Kensington
Sydney
NSW 2052</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>National Centre in HIV Epidemiology and Clinical Research University of New South Wales (UNSW)</fundingname>
      <fundingaddress>NCHECR
Level 2
376 Victoria Street
Darlinghurst
New South Wales 2010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Randomised double-blind placebo controlled study to measure the effect of antiretroviral therapy (ART) intensification with raltegravir and/or hyper-immune bovine colostrum on CD4+ T cell count in ART treated, HIV-1 infected individuals who have failed to achieve a CD4+ T cell count greater than 350 cells/µL despite persistent HIV plasma viraemia below 50 copies/mL on cART.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>St Vincent's Hospital
Victoria Street 
Darlinghurst NSW 2010</ethicaddress>
      <ethicapprovaldate>16/10/2008</ethicapprovaldate>
      <hrec>08/SVH/150</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Helen Byakwaga</name>
      <address>National Centre in HIV Epidemiology and Clinical Research (NCHECR)
Level 2
376 Victoria Street
Darlinghurst  NSW 2010</address>
      <phone>(+61 2) 9385 0900</phone>
      <fax>(+61 2) 9385 0910</fax>
      <email>hbyakwaga@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Sean Emery</name>
      <address>National Centre in HIV Epidemiology and Clinical Research (NCHECR)
Level2
376 Victoria Street
Darlinghurst  NSW 2010</address>
      <phone>(+61 2) 9385 0900</phone>
      <fax>(+61 2) 9385 0910</fax>
      <email>semery@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Helen Byakwaga</name>
      <address>National Centre in HIV Epidemiology and Clinical Research (NCHECR)
Level 2
376 Victoria Street
Darlinghurst  NSW 2010</address>
      <phone>(+61 2) 9385 0900</phone>
      <fax>(+61 2) 9385 0910</fax>
      <email>hbyakwaga@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>